Feby is a final year PhD student in Monash University, Melbourne, Australia. Her research is focussed on novel treatments for cardiorenal syndrome and mechanistic studies of non-conventional risk factors such as uraemic toxins using laboratory-based experiments. Feby is also involved in projects utilising health economic modelling, including life table models projecting the productivity impact of cardiovascular and renal diseases, as well as decision analytic model of novel pharmacotherapies for cardiovascular disease aimed to inform decision makers. Having attained a unique dual proficiency in preclinical studies and economic evaluations, her goal is to become a health economist working in the preclinical translation of novel therapies to guide their potential clinical utility, particularly for chronic diseases such as cardiovascular disease.
Inhibition of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome
Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure
Topic: Cardiovascular Pharmacotherapy, Other
Session: Basic science - Cardiomyopathies
This platform is supported by
